Information Provided By: 
Fly News Breaks for April 18, 2016
CERU, CNCE, LGND, SBBP, TGTX
Apr 18, 2016 | 08:48 EDT
Roth Capital analyst Joseph Pantginis says TG Therapeutics (TGTX) remains a Focus Pick, and reiterates a Buy rating and $33 price target on the company's shares. The analyst believes the accumulated data set and late stage aspect of the platform has de-risked the outcomes of the Phase 3studies for TG Therapeutics' TG-1101 and TGR-1202. Besides TG Therapeutics, Strongbridge (SBBP), Ligand (LGND), Concert (CNCE) and Cerulean (CERU) also fit into the "de-risked" category in the healthcare universe, Pantginis tells investors in a research note.
News For TGTX;SBBP;LGND;CNCE;CERU From the Last 2 Days
There are no results for your query TGTX;SBBP;LGND;CNCE;CERU
